The Latin America, Middle East and Africa Castrate-resistant Prostate Cancer Market would witness market growth of 9.1% CAGR during the forecast period (2020-2026). The increasing prevalence of castrate-resistant prostate cancer, rising adoption of novel drugs, coupled with an unhealthy lifestyle are the main factors predicted to boost the market growth. The requirement for fast treatment alternatives and funding in R&D by leading companies will also contribute to the growth of the market.
Prostate cancer is a type of cancer that develops into male reproductive systems. Generally, prostate cancer is slow-growing and stable but it may spread from the prostate (gland) to different part of the body like bone and lymph node. In the beginning, prostate cancer does not show any kind of symptom but in some serious cases, it causes pain during urination and can even cause a problem during sexual intercourse. Castration-resistant prostate cancer referred to prostate cancer that reached other body parts and resists medical or surgical treatment.
The primary factors boosting the development of the market are increasing geriatric population who are more vulnerable to castrate resistant prostate cancer, introduction of new drugs, existence of many authorized drugs and the proliferation of the product. Additionally, the increasing development of innovative drugs to manage unmet needs and existing treatment alternatives is also anticipated to fuel the growth of the market for castrate-resistant prostate cancer.
Moreover, rising research and development initiatives combined with growing prevalence of castrate resistant prostate cancer because of aging population is anticipated to boost the market growth. Further, presence of supportive reimbursement norms for patients is anticipated to fuel the growth of the market for castrate-resistant prostate cancer during the forecast period.
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: Castrate-Resistant Prostate Cancer Market in LAMEA is expected to register a CAGR of 9.1% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Radiotherapy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 LAMEA Castrate-Resistant Prostate Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. LAMEA Castrate-resistant Prostate Cancer Market by Therapy
4.1 LAMEA Hormonal Therapy Market by Country
4.2 LAMEA Immunotherapy Market by Country
4.3 LAMEA Chemotherapy Market by Country
4.4 LAMEA Radiotherapy Market by Country
Chapter 5. LAMEA Castrate-resistant Prostate Cancer Market by Country
5.1 Brazil Castrate-resistant Prostate Cancer Market
5.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
5.2 Argentina Castrate-resistant Prostate Cancer Market
5.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
5.3 UAE Castrate-resistant Prostate Cancer Market
5.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
5.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
5.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
5.5 South Africa Castrate-resistant Prostate Cancer Market
5.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
5.6 Nigeria Castrate-resistant Prostate Cancer Market
5.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
5.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
5.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
TABLE 1 LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 2 LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 3 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 4 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 5 LAMEA Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 6 LAMEA Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 7 LAMEA Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 8 LAMEA Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 9 LAMEA Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 10 LAMEA Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 11 LAMEA Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 12 LAMEA Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 13 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 14 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 15 Brazil Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 16 Brazil Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 17 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 18 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 19 Argentina Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 20 Argentina Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 21 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 22 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 23 UAE Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 24 UAE Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 25 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 26 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 27 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 28 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 29 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 30 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 31 South Africa Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 32 South Africa Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 33 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 34 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 35 Nigeria Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 36 Nigeria Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 37 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 38 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 39 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 40 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 41 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 42 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 43 Key Information – Sanofi S.A.
TABLE 44 Key information –Johnson and Johnson
TABLE 45 Key Information – Pfizer, Inc.
TABLE 46 Key Information – Bayer AG
TABLE 47 Key Information – Abbott Laboratories
TABLE 48 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 49 Key Information – Northwest Biotherapeutics, Inc.
TABLE 50 Key Information – Active Biotech AB
TABLE 51 key information – Astellas Pharma, Inc.
TABLE 52 Key Information – Dendreon Pharmaceuticals LLC
List of Figures
FIG 1 Methodology for the research